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Group 1 Group 2 p
General population (n) 511 266
TIMI major (%) 0.2 2.3 <0.01
TIMI minor (%) 2.0 3.4 0.22
MACCE (%) 3.5 3.4 0.9
Propensity-matched population (n) 229 229
TIMI major (%) 0 2.6 <0.05
TIMI minor (%) 1.3 3.9 0.79
MACCE (%) 4.4 2.6 0.44
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Active Versus Passive Anchoring Vascular Closure Devices: A Safety and
Efﬁcacy Comparative Analysis
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Lowell F. Satler4, Augusto Pichard5, William O. Suddath2, Rebecca Torguson6,
Ron Waksman2
1MedStar Washington Hospital Center, Washington, DC, 2Medstar Washington
Hospital Center, Washington, DC, 3Medstar Washington Hospital Center,
Washington , DC, 4Washington Hospital Center, Washington, DC, 5washsington
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Background: We evaluate the prevalence of complications and failure rates between
the most commonly used “active” anchoring vascular closure device (VCD),
AngioSeal and the “passive” anchoring VCD, Mynx, in all-comers undergoing
percutaneous coronary intervention (PCI).
Methods: A total of 4,074 patients between 2008-2014, representing an era when both
devices were available, were included. 32% were acute coronary syndromes (37%
STEMI). VCD choice was at the operator’s discretion and included AngioSeal
(n¼2910) or Mynx (1,164). Cardiogenic shock or patients receiving intra-aortic
balloon pumps were excluded. Safety was assessed by vascular complications deﬁned
as either vascular injury (perforation, dissection, acute limb ischemia, arteriovenous
ﬁstula, pseudoaneurysm with thrombin injection, or surgical repair) or access-site
bleed (hemoglobin drop >3 g/dL requiring transfusion, retroperitoneal bleed, or he-
matoma >5cm, or the composite of both. Efﬁcacy was evaluated by device failure
deﬁned as inability to achieve immediate hemostasis, or additional hemostatic
mechanisms require. Outcomes at 30-days were evaluated.
Results: Groups (AngioSeal vs. Mynx) were fairly balanced with regards to bleeding
risk factors of gender (male, 65% vs. 66%), body mass index (306 vs. 307), heart
failure class III/IV (5% vs. 6%), chronic kidney disease (15% vs. 17%), use of
glycoprotein IIb/IIIa inhibitor (5% vs. 4%) or bivalirudin (86% vs. 88%), all p >0.5.
The AngioSeal group was slightly younger (6412 vs. 6512, p < 0.001) with less
peripheral arterial disease (11.3% vs. 13.9%, p ¼0.03), and increased 7F sheath use
compared with Mynx (59% vs. 22%, p < 0.001). Safety and efﬁcacy outcomes were
similar between groups (table).
Conclusions: AngioSeal and Mynx appear to be equally safe and efﬁcacious VCDs
following PCI. The passive anchoring system may prove desirable as no intra-arterial
anchor remains upon device removal.Outcomes
p valueAngioSeal (n¼2,910) Mynx (n¼1,164)
Safety
Vascular injury 0.30% 0.80% 0.09
Access-site bleed 1.90% 1.40% 0.8
Composite safety 2.30% 1.50% 0.6
Efﬁcacy
Device failure 7.50% 8.70% 0.4TCT-845
Femoral Approach with Systematic Use of FemoSeal Closure Device
Compared to Radial Approach in Primary Angioplasty: a Propensity-matched
Comparison
Stefano Rigattieri1, Alessandro Alonzo2, Francesca Giovannelli2, Cristian Di Russo1,
Alessandro Sciahbasi1, Andrea Berni2
1Interventional Cardiology, Sandro Pertini Hospital, Rome, Italy, 2Interventional
Cardiology, Sant’Andrea Hospital, Rome, Italy
Background: Radial approach (RA) has been shown to reduce access-related
bleedings as compared to femoral approach (FA). However, although the risk of
femoral bleeding can be reduced with the adoption of vascular closure devices (VCD),
there are few data about the comparison of RA and FA with VCD, particularly in
patients at high risk of bleeding such as those undergoing primary percutaneous
coronary intervention (pPCI). The FemoSeal (St.Jude Medical,MN,USA) is a
sandwich type, fully resorbable VCD that has been associated with a low rate of
access-site bleeding and vascular complications. Aim of this study was to compare the
incidence of bleedings, deﬁned according to the Thrombolysis in Myocardial
Infarction (TIMI) criteria, and of major adverse cardiac and cerebrovascular events
(MACCE) in a population of patients undergoing primary angioplasty through RA or
FA with systematic closure by FemoSeal.
Methods:We included in this retrospective registry 777 patients who underwent pPCI
at two high-volume Centers from years 2010 to 2013. Exclusion criteria were the
implantation of intra-aortic balloon pump and the achievement of femoral hemostasis
by other means than the FemoSeal. The study population was divided in RA pa-
tients, enrolled in Center A (Group 1, n¼511) and FA patients, enrolled in Center BB246 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT A(Group 2, n¼266). We performed multivariate analysis and propensity-score matching
in order to adjust for clinical and procedural confounders.
Results: Main results of the study are provided in the Table. At multivariate analysis,
the following predictors of bleeding were identiﬁed: FA (OR 3.2, 95% C.I. 1.3-7.5),
use of Gp IIb/IIIa blockers (OR 3.6, 95% C.I. 1.5-8.7) and heart rate at presentation
(OR 1.04, 95% C.I. 1.02-1.07).
Conclusions: In primary PCI the rate of TIMI major bleedings was higher in FA with
closure by FemoSeal as compared to RA, whereas the rates of minor bleedings and
of MACCE were similar.TCT-846
Radial-to-femoral access crossover is not associated with adverse outcomes in the
setting of primary percutaneous coronary intervention
Lorenzo Azzalini1, Razi Khan1, Malek Al-Hawwas1, Raja Hatem1, Annik Fortier1,
Philippe L. L’Allier1, Hung Q. Ly1
1Montreal Heart Institute, Montreal, QC, Canada
Background: We aimed to describe the impact of the vascular access used when
patients are treated with primary percutaneous coronary intervention (PPCI) and to
assess whether this translates into differences in angiographic outcomes.
Methods: ST-elevation myocardial infarction (STEMI) patients undergoing PPCI
were divided into three groups: successful radial access (RA), successful femoral
access (FA) and Crossover (failed RA with need for bailout FA) groups. Vascular
access-related time (VART) was deﬁned as the delay in PPCI that can be attributed to
vascular access-related issues. Study endpoint was the ﬁnal corrected TIMI frame
count (CTFC). Multivariable analysis was used to identify predictors of RA failure
(RAF: FA+Crossover).
Results: We included 241 patients (RA n¼172, FA n¼49, Crossover n¼20).
Mean VART was longer in Crossover (10.3 (8.8-12.4) min), relative to RA (4.1
(3.2-5.5) min) and FA (4.6 (3.4-8.4) min, p< 0.001). A similar situation was
found for time-to-ﬁrst-device (Crossover: 22.5 (20.3-32.0) min; RA: 15.0 (12.0-
19.8) min; FA: 17.9 (13.5-22.3) min; p< 0.001) and total procedure time
(Crossover: 60.3 (51.6-71.5) min; RA: 46.8 (38.1-59.7) min; FA: 52.3 (41.9-
74.7) min; p< 0.001). No differences in CTFC were observed (Crossover: 26
(18-32) frames; RA: 24 (18-32) frames; FA: 25 (16-34) frames; p¼0.625). Killip
class IV (OR 3.628, 95% CI: 1.098-11.981, p¼0.035), cardiopulmonary resus-
citation prior to arrival (OR 3.572, 95% CI: 1.028-12.407, p¼0.045) and
glomerular ﬁltration rate (OR 0.861, 95% CI: 0.758-0.978, p¼0.021) were in-
dependent predictors of RAF.
Conclusions: In the setting of PPCI, radial-to-femoral access crossover can lead to
VART delays that do not impact angiographic outcomes, in comparison with suc-
cessful RA. Killip class IV, cardiopulmonary resuscitation prior to arrival and
impaired renal function are independent predictors of RAF in STEMI patients un-
dergoing PPCI.
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Primary Percutaneous Coronary Intervention For ST-elevation Myocardial
Infarction
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Background: Patients undergoing primary percutaneous coronary intervention (PCI)
for ST-elevation myocardial infarction (STEMI) are at high risk of femoral vascular
complications (VC). In spite of the growing use of radial approach, femoral remains
the most common in primary PCI. The use of femoral vascular closure devices
(VCDs) has expanded in recent years despite previous controversial trials. Angio-
Seal is a collagen-based plug/anchor intravascular device and Exo-Seal is an
extravascular polyglykolacid plug. Objective: to evaluate safety and efﬁcacy, and to
compare these VCDs in primary PCI.bstracts/Vascular Access and Intervention - Femoral (includes closure devices)
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: We included 827 consecutive patients who underwent primary PCI by
femoral access in our institution between August 2009 to October 2013 with a 6
months follow-up. Primary end point was the presence of VC deﬁned as a composite
of hematoma> 6 cm, recurrent bleeding, pseudoaneurysm, arteriovenous ﬁstula,
arterial thrombosis or retroperitoneal bleeding.
Results: 404 (48.8%) patients received Angio-Seal and 423 (51,2%) Exo-Seal. 39
(4,7%) patients had a VC with a similar incidence of events between the 2 VCDs: 18
(4,4%) in Angio-Seal and 21 (4,9%) in Exo-Seal (p¼0.7). Risk of VC was
signiﬁcantly associated with body mass index (p¼0.01), sheath size (p¼0.04), pres-
ence of chronic kidney disease (p¼0.005) and peripheral arterial disease (p¼0.03).
There was no fatal complications. Most of the pseudoaneurysms were resolved with
compression and/or thrombin, only 2 of them and 1 retroperitoneal bleeding required
vascular surgery.
Conclusions: Although radial approach is increasing in recent years, femoral
remains the most frequent in primary PCI. VC after femoral VCDs in patients un-
dergoing primary PCI, have a low but not negligible incidence despite being implanted
by interventional cardiologists experienced in femoral access. VC were signiﬁcantly
associated with individual (body mass index, chronic kidney disease, peripheral arterial
disease) and procedure-related (sheath size) characteristics. Safety and efﬁcacy of both
(Angio-Seal and Exo-Seal) VCDs is similar after primary PCI.TCT-848
Mynx Vascular Closure Device Achieves Reliable Closure and Hemostasis
of Large Bore Percutaneous Trans-Femoral Venous Access in a Porcine Vascular
Model: Acute and 30 Day Evaluation using Angiography, Ultrasound, and
Histology
sanjay s srivatsa1, Arjun Srivatsa1, Taylor Spangler2
1Heart Artery and Vein Center Fresno CA, Fresno, CA, 2VDx – Preclinical Pathology
Services, Davis, CA
Background: Vascular closure device (VCD) based venous closure has been anec-
dotally reported but systematic evaluation of the reparative response of the vessel wall
to venous closure is lacking. The need to control groin complications, and minimize
risks associated with postponed sheath removal under conditions of persistent anti-
coagulation, has generated interest in the role of vascular closure devices for venous
access closure. We sought to characterize the vessel wall response to venous closure,
both acutely and in delayed fashion at 30 days using angiography, ultrasound and
histology.
Methods: Ten (10) venous 7F sheaths were deployed in the femoral veins of swine.
Bilateral venous access sites were subsequently closed utilizing manual compression
(control arm, n¼4) or a closure device utilizing an extravascular polyethylene glycol
sealant (MynxGrip Treatment arm, n¼6). Acute (post-closure), 3-day and 30-day
vascular ultrasound, as well as venography was used to assess outcomes. Gross pa-
thology and histology were obtained at the 30 day endpoint for all femoral venous
closure sites.Each animal was evaluated for venous thromboembolism to downstream
tissues vena cava, heart, and lungs.
Results: Hemostasis was successfully achieved in all cases without access site
complications. Venography and ultrasound conﬁrmed normal ilio-femoral anatomy
and ﬂow at all study time points. Gross pathology and histopathology revealed no
evidence of deep vein thrombosis, and no abnormalities were seen in the vena cava,
heart or lungs. Histology (at 30 days) showed complete healing of the vein wall access
site, with a small focus of chronic inﬂammation and ﬁbrosis in the perivascular
adventitial tissue of the access tract. There was no microscopic evidence of the sealant.
The tissue tract showed mild discrete inﬂammation (foamy macrophages, lympho-
cytes, plasma cells) with micro-granulomas centered on residual red cells in both
treatment and control groups.
Conclusions: This study provides novel insight into healing mechanisms following
femoral vein closure and the bioresorptive role of MynxGrip extravascular sealant in
achieving effective venous closure, while preserving long term vessel patency without
thromboembolism.TCT-849
Preclosure of vascular access site with the suture-mediated ProGlide system
during transfemoral TAVI and MitraClip implantation
William KF. Kong1
1National University Hospital, Singapore, Singapore, Singapore
Background: The ProGlide closure system is becoming popular for the percutaneous
delivery of suture for closing the vascular access site of patients who have undergone
structural interventional procedures using 5F to 21F sheaths. This study is intended to
demonstrate the safety, effectiveness and feasibility of a suture-mediated ProGlide for
access site closure after transfemoral transcatheter aortic valve implantation (TAVI)
and transfemoral MitraClip.
Methods: ProGlide closure was used between 2010 and 2013 in 57 patients in our
centre. The ProGlide sutures were deployed in a preclose technique before the
insertion of the large caliber sheath. Achieving effective hemostasis and no further
access site-related vascular or hemorrhagic complications during the whole hospital
stay is considered success of the closure technique.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VasculResults: Patients were 73+/-6.5 years old with a logistic EuroSCORE of 22.2+/-12.4.
There were total of 57 patients deemed high risk as surgical candidates undergone
percutaneous therapy for transfemoral TAVI with Edwards SAPIEN valves (n¼31)
and MitraClip procedure (n¼26). The overall success rate of the ProGlide closure was
98.3%(one patient had diminished pulses distal to closure site that needed surgical
intervention). The success rate remained at 100% among the patients on dual anti-
platelet therapy (DAPT) or on anticoagulants. None of the patients that were examined
with ultrasound demonstrated an AV ﬁstula, aneurysm, hematoma or local thrombosis
related to the ProGlide device.
Conclusions: This study demonstrated that the suture-mediated ProGlide system is a
safe, simple and highly effective method to close the large arterial access site after
transfemoral TAVI and large venous sites of 24Fr as needed in patients undergoing
MitraClip procedure despite on platelet inhibitors or anticoagulation. Additionally, use
of the ProGlide system can result in shorter procedure time, duration to achieve he-
mostasis and also shorter length of hospital stay.TCT-850
Patients undergoing PCI via the femoral artery in a default radial centre
have very high BARC bleeding rates and subsequent bleeding 30 day and
1 year mortality
Mohammad Muezz Uddin1, Shantu Bundhoo1, Senthil K. Elangovan1,
Fairoz B. Abdul1, Nick Ossei-Gerning1, RIchard Anderson1, Tim D. Kinnaird1
1University Hospital of Wales, Cardiff, Wales
Background: Increasingly the trans-radial route (TR) is preferred over the trans-
femoral route (TF) for PCI. However even in high volume default TR centres a small
cohort of patients are required to undergo TF PCI. We examined the demographics,
procedural and bleeding outcomes of patients undergoing PCI via the TF in a single
high volume UK centre.
Methods: The patient demographics procedure and outcomes of 5379 patients un-
dergoing PCI between 2009 and 2012 were examined. 559(10.4%) patients underwent
PCI via the TF route reviewed for Hb drop 3g/dl or more, overt bleeding, Transfusion
with in 7 days post PCI, Doppler US/ CT abdomen.
Results: 559(10.4%) patients underwent PCI via the TF route and these patients were
more often female, older, lower body weight, shocked and undergoing complex
procedures than patients in the TR cohort. In the TF group 79 patients (16.4%)
experienced bleeding with 1 each BARC Type 5a and 5b bleed each, 3 BARC Type
3b bleeds, 17 Type 3a bleeds and 57 Type 2 bleeds. Within the TF cohort patients with
bleeding when compared to TF patients without bleeding were less likely to have
stable angina (13.9% vs. 38.5%, p< 0.0001), more likely to be undergoing primary
PCI (30.4% vs. 9.4%, p< 0.0001), present with cardiogenic shock (24.1% vs. 3.5%,
p< 0.0001), have sheath sizes greater than 6F used and have a lower BMI (26.0
vs. 32.3 in females and 27.2 vs. 30.0 in males). Mortality at 30 days (15.2% vs. 1.9%,
p < 0.0001) and 1 year (25.3% vs. 5.2%, p< 0.0001) was signiﬁcantly higher in the
bleeding group. Major bleeding was an independent predictor of 30 day and 1year
mortality.
Conclusions: In a high volume default TR centre the incidence of BARC-
deﬁned bleeding was extremely high in TF PCI patients with excess mortality at
30 days and 1 year. Therefore TF PCI cases undertaken in a default TR centre
cases require meticulous peri-procedural and post-procedural care to minimise
complications.ar Access and Intervention - Femoral (includes closure devices) B247
